TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20584327

Group type: EXPERIMENTAL
Intervention: Pain Cluster
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Fatigue Cluster
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Domestic Cluster
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Impairment Cluster
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Affective Cluster
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Social Cluster
Number of subjects: 788
Study: 20584542

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily until PD or unacceptable toxicity
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg once daily
Number of subjects: 36
Study: 20585012

Group type: EXPERIMENTAL
Intervention: Pulmonary vascular resistance >32 Wood units
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: PAH associated with portal hypertension
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Modified New York Heart Association/World Health Organization functional class IV
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Men >60 years of age
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Family history of PAH
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Renal insufficiency
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: PAH associated with connective tissue disease
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Functional class III
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Mean right atrial pressure
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Resting systolic blood pressure and heart rate
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: 6-minute walk distance
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Percent predicted carbon monoxide diffusing capacity
Number of subjects: 2716

Group type: EXPERIMENTAL
Intervention: Pericardial effusion on echocardiogram
Number of subjects: 2716
Study: 20588167

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 78
Study: 20589868

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 123
Study: 20591142

Group type: EXPERIMENTAL
Intervention: Primary prevention of cardiovascular disease (CVD)
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Physician-level assessment
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Patient-level assessment
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Fasting blood sample analysis
Number of subjects: 7641
Study: 20591191

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14), 2 capsules a day for 6-12 weeks, up to the 24th-25th week of gestation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20593018

Group type: EXPERIMENTAL
Intervention: rdESAT-6 and CFP-10 skin test reagent (0.01 microg or 0.1 microg injected intradermally)
Number of subjects: 42
Study: 20594195

Group type: EXPERIMENTAL
Intervention: Bendamustine 90 mg/m²
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bendamustine 120 mg/m²
Number of subjects: 9
Study: 20595284

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneous injections every other week
Number of subjects: 127
Study: 20595516

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT) with fludarabine/cyclophosphamide-based conditioning
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT) with MRD monitoring
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (alloSCT)
Number of subjects: 100
Study: 20597081

Group type: EXPERIMENTAL
Intervention: Pa-Never
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Pa-Past
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Diagnosis after newborn or prenatal screening
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 1700
Study: 20598482

Group type: EXPERIMENTAL
Intervention: Therapeutic neovascularization
Number of subjects: 47
Study: 20598570

Group type: EXPERIMENTAL
Intervention: Retrievable Option inferior vena cava (IVC) filter
Number of subjects: 100
Study: 20598843

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR genotype
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 5-HTTLPR polymorphism
Number of subjects: 176
Study: 20599053

Group type: EXPERIMENTAL
Intervention: Modified Fear-Avoidance Beliefs Questionnaire (FABQ)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tampa Scale of Kinesiophobia (TSK-11)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Shoulder Pain and Disability Index (SPADI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FABQ-W (work beliefs subscale)
Number of subjects: 80
Study: 20599188

Group type: EXPERIMENTAL
Intervention: GSK598809 (selective D(3) receptor antagonist)
Number of subjects: 19
Study: 20599337

Group type: EXPERIMENTAL
Intervention: Couples-based intervention for self-management of hyperlipidemia
Number of subjects: 250
Study: 20602477

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EvES)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 187
Study: 20605360

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 17
Study: 20605397

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 29
Study: 20605934

Group type: EXPERIMENTAL
Intervention: SU14813 (200 mg/day on schedule 4/1)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: SU14813 (100 mg/day with continuous daily dosing)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: SU14813
Number of subjects: 77
Study: 20606544

Group type: EXPERIMENTAL
Intervention: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks with conventional immunotherapy (Group I and II)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Rituximab administered intravenously at 375 mg/m2 on each of 4 consecutive weeks without conventional immunotherapy (Group III)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rituximab dosing based on body weight
Number of subjects: 25
Study: 20606683

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor therapy (AI); specific dosage and duration not mentioned.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (without AIMSS); specific dosage and duration not mentioned.
Number of subjects: 52
Study: 20608766

Group type: EXPERIMENTAL
Intervention: Baseline IP-10 < 150 pg/ml
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Baseline IP-10 levels
Number of subjects: 21
Study: 20609468

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg twice daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Olaparib 100 mg twice daily
Number of subjects: 57
Study: 20609706

Group type: EXPERIMENTAL
Intervention: Sirna-027 (100, 200, 400, 800, 1200, or 1600 microg/eye)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sirna-027 (100 and 200 microg doses)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sirna-027 (up to 1600 microg/eye)
Number of subjects: 26
Study: 20610186

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily for 90 days
Number of subjects: 30
Study: 20610635

Group type: EXPERIMENTAL
Intervention: Elevated bone turnover (EBT) group (n = 13)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal bone turnover group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nutritional support (not quantified in the abstract)
Number of subjects: 39
Study: 20615492

Group type: EXPERIMENTAL
Intervention: Combined surgery (n = 64)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Consecutive surgery (n = 56)
Number of subjects: 120
Study: 20616117

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 275
Study: 20616163

Group type: EXPERIMENTAL
Intervention: Holter monitoring in patients on hemodialysis
Number of subjects: 239
Study: 20617532

Group type: EXPERIMENTAL
Intervention: Presence of anti-Sa antibodies at inclusion, especially at higher titers
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Low titer of any particular antibody
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Reversion of RF and anti–CCP-2 antibodies
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Acquisition of RF or anti–CCP-2 after inclusion
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Initial positivity for RF and anti–CCP-2 antibodies
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Anti-CCP-2 prevalence
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Presence of anti-Sa antibodies
Number of subjects: 253
Study: 20619378

Group type: EXPERIMENTAL
Intervention: Invaplex 50 (100%)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: S. flexneri 2a LPS (71%)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 240 microg dose
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Invaplex 50 (38.5%)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LPS (30.8%)
Number of subjects: 32
Study: 20619396

Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control groups (without PTSD and unexposed)
Number of subjects: 73
Study: 20620231

Group type: EXPERIMENTAL
Intervention: Coronary revascularization (CR)
Number of subjects: 759

Group type: COMPARATOR
Intervention: No prior coronary revascularization (CR)
Number of subjects: 759
Study: 20620717

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1492
Study: 20624109

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (three doses of 4 g)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Platelet concentrate (two units)
Number of subjects: 1
Study: 20624517

Group type: EXPERIMENTAL
Intervention: Postoperative delirium diagnosis based on DSM-IV criteria
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Advanced age, preoperative cognitive impairment, ongoing episode of major depression, anaemia, atrial fibrillation, prolonged intubation, postoperative hypoxia
Number of subjects: 563
Study: 20625116

Group type: EXPERIMENTAL
Intervention: IDH1 mutations (IDH1m) in patients with normal cytogenetics (CN-AML)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: IDH2 mutations (IDH2m) in patients with normal cytogenetics (CN-AML)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Favorable genotype in CN-AML (NPM1m or CEBPAm without FLT3-ITD or IDH1m)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Multivariate analysis including age, WBC count, four-gene favorable genotype, and IDH2m
Number of subjects: 520
Study: 20625390

Group type: EXPERIMENTAL
Intervention: Higher year 7 fibrinogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher year 7 CRP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher year 5 fibrinogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Year 7 CRP among participants with greater than 10 pack-years of cigarette exposure
Number of subjects: 0
Study: 20626754

Group type: EXPERIMENTAL
Intervention: Bendamustine (120 mg/m² on days 1-2 of a 21-day cycle, for up to six cycles)
Number of subjects: 69
Study: 20627488

Group type: EXPERIMENTAL
Intervention: Breastfed infants (BM group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Iron-fortified formula (F group)
Number of subjects: 76
Study: 20627920

Group type: EXPERIMENTAL
Intervention: Albuterol (180 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: During exacerbation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Recovery results
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline (clinically stable)
Number of subjects: 15
Study: 20629472

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Moxifloxacin ophthalmic solution 0.5%
Number of subjects: 1350
Study: 20630061

Group type: EXPERIMENTAL
Intervention: Temsirolimus administered intravenously at 25 mg weekly (Study A)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Everolimus administered orally at 30 mg weekly and erlotinib at 150 mg daily (Study B)
Number of subjects: 21
Study: 20630062

Group type: EXPERIMENTAL
Intervention: Chronic Care Model (CCM) intervention in the intervention region
Number of subjects: 4174

Group type: COMPARATOR
Intervention: Control region
Number of subjects: 4174
Study: 20630688

Group type: EXPERIMENTAL
Intervention: DCVT
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: MCVT
Number of subjects: 725
Study: 20631018

Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: IGF-I generation test
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Baseline IGF-I/GH determinations
Number of subjects: 493
Study: 20631203

Group type: EXPERIMENTAL
Intervention: PROP supertasters (n = 27)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nontasters (n = 20)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gustin gene polymorphism (rs2274333)
Number of subjects: 75
Study: 20631232

Group type: EXPERIMENTAL
Intervention: Tear film osmolarity testing
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Conjunctival staining
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Corneal staining
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Meibomian dysfunction assessment
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Tear film breakup time (TBUT)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Schirmer test without anesthesia
Number of subjects: 314

Group type: COMPARATOR
Intervention: Standard threshold-based classification
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Clinical assessment of dry eye severity
Number of subjects: 314
Study: 20631556

Group type: EXPERIMENTAL
Intervention: Fluoxetine therapy
Number of subjects: 17
Study: 20631574

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard opioid detoxification)
Number of subjects: 0
Study: 20632098

Group type: EXPERIMENTAL
Intervention: Gastroenterologist-guided sedation
Number of subjects: 91

Group type: COMPARATOR
Intervention: Anesthesiologist-guided sedation
Number of subjects: 91
Study: 20633428

Group type: EXPERIMENTAL
Intervention: ECT (6 bilateral treatments, outpatient, twice-weekly)
Number of subjects: 20
Study: 20633821

Group type: EXPERIMENTAL
Intervention: BMIPP SPECT
Number of subjects: 507

Group type: COMPARATOR
Intervention: BMIPP + initial diagnosis
Number of subjects: 507
Study: 20634241

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 135
Study: 20634373

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) on days 1, 29, 57 and 85; Fludarabine orally, 40 mg/m(2) on days 1-5, 29-34, 57-61 and 85-89
Number of subjects: 29

Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fludarabine and rituximab combination therapy
Number of subjects: 29
Study: 20634483

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators
Number of subjects: 15381

Group type: EXPERIMENTAL
Intervention: CRT with pacemaker
Number of subjects: 15381

Group type: EXPERIMENTAL
Intervention: CRT with defibrillator
Number of subjects: 15381

Group type: COMPARATOR
Intervention: No device
Number of subjects: 15381
Study: 20634684

Group type: EXPERIMENTAL
Intervention: KNOW FIVE - STAY ALIVE program
Number of subjects: 0

Group type: COMPARATOR
Intervention: FAST program
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIH brochure 'Know Stroke. Know the signs, Act in time'
Number of subjects: 0
Study: 20634719

Group type: EXPERIMENTAL
Intervention: PPA less than 10%
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: PPA between 10 and 20%
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: PPA between 20 and 30%
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: PPA more than 30%
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: PWV in presence of hypertension
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: PWV in presence of diabetes
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: PWV in participants with heart disease
Number of subjects: 1042
Study: 20634785

Group type: EXPERIMENTAL
Intervention: Diannexin treatment
Number of subjects: 0
Study: 20636419

Group type: EXPERIMENTAL
Intervention: Inadequate or no antimicrobial treatment at origin
Number of subjects: 337

Group type: COMPARATOR
Intervention: Adequate antimicrobial regimen according to guidelines
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Transferred patients
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Complications and operations
Number of subjects: 337
Study: 20637534

Group type: EXPERIMENTAL
Intervention: Biomechanical device treatment
Number of subjects: 46
Study: 20637584

Group type: EXPERIMENTAL
Intervention: High omega-3 to omega-6 PUFA ratio (Q75)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low omega-3 to omega-6 PUFA ratio (Q25)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Specific bronchial challenge with grass pollen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 20638196

Group type: EXPERIMENTAL
Intervention: Three cycles of CHOP chemotherapy and radiation to a dose of 45 Gy in 25 fractions using a shrinking field technique
Number of subjects: 33
Study: 20644013

Group type: EXPERIMENTAL
Intervention: Melody valve implantation
Number of subjects: 136
Study: 20644097

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 20645885

Group type: EXPERIMENTAL
Intervention: Torcetrapib on top of optimal atorvastatin therapy
Number of subjects: 1624

Group type: COMPARATOR
Intervention: Placebo on top of optimal atorvastatin therapy
Number of subjects: 1624
Study: 20646242

Group type: EXPERIMENTAL
Intervention: Therapeutic thoracentesis (TT)
Number of subjects: 26
Study: 20646244

Group type: EXPERIMENTAL
Intervention: Thoracocentesis
Number of subjects: 10
Study: 20647554

Group type: EXPERIMENTAL
Intervention: IGIV-C
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 20647561

Group type: EXPERIMENTAL
Intervention: Clinical SYNTAX Score (CSS) calculated by multiplying the SYNTAX Score to a modified ACEF score.
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Clinical SYNTAX Score (CSS)
Number of subjects: 512
Study: 20648206

Group type: EXPERIMENTAL
Intervention: mild lumbar decompression procedure
Number of subjects: 75
Study: 20650435

Group type: EXPERIMENTAL
Intervention: CYP2C19 variant carriers (n = 80)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: CYP2C19 variant
Number of subjects: 126
Study: 20650436

Group type: EXPERIMENTAL
Intervention: TAXUS Express paclitaxel-eluting stent
Number of subjects: 474
Study: 20650686

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy for up to six cycles, followed by single-agent bevacizumab until disease progression
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 or 15 mg/kg every 3 weeks) plus standard chemotherapy
Number of subjects: 2212
Study: 20650871

Group type: EXPERIMENTAL
Intervention: Cereal feeding to induce polyclonal gluten-specific T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cereal feeding (wheat, barley, rye)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunodominant peptides from omega-gliadin (wheat) and C-hordein (barley)
Number of subjects: 0
Study: 20651074

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/d with a 3-month low-dose prednisone taper
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study: 20651099

Group type: EXPERIMENTAL
Intervention: Culturally tailored nutrition education program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 79
Study: 20651274

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transcranial Doppler monitoring
Number of subjects: 60
Study: 20653948

Group type: EXPERIMENTAL
Intervention: IMP321 (LAG-3Ig) administered subcutaneously every two weeks for 24 weeks (12 injections) alongside paclitaxel (80 mg/m2 weekly for 3 weeks out of 4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IMP321 (LAG-3Ig)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Historical control group (not specified in detail)
Number of subjects: 30
Study: 20656559

Group type: EXPERIMENTAL
Intervention: MODS culture
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Lowenstein-Jensen culture
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Gastric-aspirate specimens
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Gastric-aspirate specimens (second specimen)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Gastric-aspirate PCR
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Duplicate gastric-aspirate specimens for MODS culture
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 218
Study: 20657770

Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI)
Number of subjects: 25
Study: 20658481

Group type: EXPERIMENTAL
Intervention: HRCT scans
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Histological analysis
Number of subjects: 15
Study: 20658621

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: T2*-MRI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MUGA scan
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Serum ferritin measurement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hepatic iron content measurement
Number of subjects: 30
Study: 20659883

Group type: EXPERIMENTAL
Intervention: Initial serum glucose level >140 mg/dl
Number of subjects: 672
Study: 20660050

Group type: EXPERIMENTAL
Intervention: Thymidine analogs (iododeoxyuridine or bromodeoxyuridine) administered 8 days to 4 years prior to death.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Estimation of β-cell longevity using (14)C levels from DNA purified from pancreatic islets.
Number of subjects: 10